CXCL8 and renal cell carcinoma: From hepatocellular carcinoma and renal cell carcinoma analyses, higher baseline plasma levels of IL‐8 were correlated with worse outcomes in treatment with angiogenesis inhibitors, such as sunitinib or BEV.